Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627145 | 0.92 | PDE4B (0.77) | PDE4BCSF1R | |
| SCHEMBL4627111 | 0.92 | PDE4B (0.69) | PDE4BCSF1R | |
| SCHEMBL4627622 | 0.88 | PDE4B (0.73) | PDE4BCSF1R | |
| SCHEMBL1275623 | 0.84 | PDE4B (1.00) | PDE4BCSF1R | |
| SCHEMBL4627414 | 0.84 | PDE4B (0.57) | PDE4BCSF1R | |
| SCHEMBL4627626 | 0.83 | PDE4B (0.59) | PDE4BCSF1R | |
| SCHEMBL14198945 | 0.83 | PDE4B (0.83) | PDE4BCSF1R | |
| Hydrochloric Acid SCHEMBL4625816 | 0.82 | PDE4B (0.82) | PDE4BCSF1R | |
| SCHEMBL8299882 | 0.80 | PDE4B (0.70) | PDE4BCSF1R | |
| SCHEMBL14198944 | 0.78 | PDE4B (0.67) | PDE4BCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | claimed |
| EP-1673086-B1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2008-01-23 | — | — | EP | claimed |
| JP-2007506703-A | — | — | 2007-03-22 | — | — | JP | claimed |
| EP-1673086-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | claimed |
| WO-2005030212-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | claimed |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| EP-1673086-B1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1673086-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030212-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885CSF1R 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.